3 active not recruiting, 3 completed, 1 recruiting. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Active not recruiting 3, Completed 3, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow histrelin: new trials by email Literature Review of histrelin trials Research Report on histrelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Bicalutamide, Buserelin, Darolutamide - Prostate Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 2050 | 2021-12-06 | 2026-08-17 |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-11-05 |
| Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 3 | Active not recruiting | NRG Oncology | 2753 | 2021-01-21 | 2026-08-17 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
| Histrelin Subcutaneous Implant in Children With Central Precocious Puberty Histrelin Subcutaneous Implant - Central Precocious Puberty | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 36 | 2004-09-01 | 2021-01-08 |
| Study of Histrelin Subdermal Implant in Patients With Prostate Cancer Histrelin hydrogel implant, Zoladex goserelin implant - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 59 | 2000-05-01 | 2024-01-02 |
| Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer histrelin acetate - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 138 | 2000-04-01 | 2024-01-02 |
Prostatic Neoplasms (5) · Neoplasm Metastasis (1) · Puberty, Precocious (1) · Salivary Gland Adenoma, Pleomorphic (1)
Endo USA Inc., a Keenova Therapeutics Company (3) · NRG Oncology (2) · SWOG Cancer Research Network (1) · VA Office of Research and Development (1)
United States (4) · Canada (2) · Chile (1) · Colombia (1) · Mexico (1) · Switzerland (1)
Abhishek Solanki, MD MS (1) · Brian Chapin (1) · Erica A Eugster, MD (1) · Neil B Desai (1) · Paul L Nguyen (1) · Regulatory Division (1)
PMID 16515997, PMID 24295437, PMID 25803268
U10CA180868 (2), I01CX002277 (1), U10CA180888 (1)